We are live on ! Find out more
CLLS

Cellectis

30 hedge funds and large institutions have $26.1M invested in Cellectis in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

0.05% more ownership

Funds ownership: 13.68%13.73% (+0.05%)

12% less funds holding

Funds holding: 3430 (-4)

14% less capital invested

Capital invested by funds: $30.2M → $26.1M (-$4.12M)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

79% less call options, than puts

Call options by funds: $17K | Put options by funds: $82K

Holders
30
Holders Change
-4
Holders Change %
-11.76%
% of All Funds
0.43%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
9
Reduced
4
Closed
6
Calls
$17K
Puts
$82K
Net Calls
-$65K
Net Calls Change
-$88K

CLLS Hedge Fund Activity: Q1 2024 in Review

30 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q1 2024, worth a combined $26.1M — down 14% from $30.2M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CLLS and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 9 added.

The largest buyer was Principal Financial Group, adding an estimated $68.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $54.8K sold.

  • 30 institutional investors held Cellectis (CLLS) as of Q1 2024, down from 34 in Q4 2023.
  • Funds reported $26.1M of Cellectis stock for Q1 2024, down 14% quarter-over-quarter.
  • 3 funds opened new Cellectis positions in Q1 2024 and 6 closed out, a net change of -3 holders.
  • The largest Cellectis buyer in Q1 2024 was Principal Financial Group, an estimated $68.9K added.
  • The largest Cellectis seller in Q1 2024 was Citadel Advisors, an estimated $54.8K sold.

Based on aggregated 13F filings for Q1 2024.